JPMorgan Chase & Co. lifted their price target on shares of argenex from $830.00 to $925.00 and gave the company an "overweight" rating in a research report on Friday...
MarketBeat·10h ago
More News
argenex (NASDAQ:ARGX) Sets New 52-Week High - Here's What Happened
argenex (NASDAQ:ARGX) Reaches New 52-Week High - Here's Why...
MarketBeat·1d ago
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View
HALO posts strong third-quarter results with earnings and revenues topping estimates and raises 2025 guidance on robust royalty growth.
Zacks·5d ago
INCY or ARGX: Which Is the Better Value Stock Right Now?
INCY vs. ARGX: Which Stock Is the Better Value Option?
Zacks·24d ago
INCY vs. ARGX: Which Stock Is the Better Value Option?
INCY vs. ARGX: Which Stock Is the Better Value Option?
Zacks·1mo ago
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
Zacks·1mo ago
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Here is how argenex SE (ARGX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Zacks·2mo ago
KMDA or ARGX: Which Is the Better Value Stock Right Now?
KMDA vs. ARGX: Which Stock Is the Better Value Option?
Zacks·2mo ago
15 names that Morgan Stanley’s analysts expect to move meaningfully on earnings
Investing.com -- Morgan Stanley expects a “normal” earnings beat rate for the second quarter, with S&P 500 EPS growth forecast at 5% year-over-year and sales up 4%.
investing.com·4mo ago
EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
EXEL vs. ARGX: Which Stock Is the Better Value Option?